In the phase 3 KOMET trial, Koselugo delivered a statistically significant and clinically meaningful objective response rate ...

Nov. 12, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company ... into ...

Revenue: Revenue for the three months ended September 30, 2024, increased to approximately $1,958,000 compared to $397,000 ...

Akari Therapeutics, Plc (Nasdaq: AKTX), an innovative biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, announces shareholder approval in connection with ...

When it comes to pre-revenue biotechs, it's often a struggle to build an investment thesis beyond "if the medicine works, the ...

A stock market crash might sound terrifying to some but it can also present a once-in-a-lifetime opportunity to accumulate generational wealth.

Regulators are also reviewing Teva’s application for its Prolia biosimilar candidate. The FDA’s decisions are expected ...

In organ donation and transplantation, the high demand for organs exceeds supply, greatly, leading to limited access to transplantation. The waiting lists for a heart transplant in the UK increased by ...

Basel, October 27, 2024 – Novartis today presented 12-month data from the Phase III APPEAR-C3G study at American Society of Nephrology (ASN) Kidney Week 2024 showing that patients with C3 ...

Trinity Biotech (TRIB) announced the acquisition of EpiCapture. This acquisition marks Trinity Biotech’s strategic expansion into the oncology diagnostics market. Prostate cancer is the most ...

Purple Biotech (PPBT) has released an update. Purple Biotech has unveiled promising data for its innovative CAPTN-3 antibody platform, which targets triple-negative breast cancer and non-small ...